Aspirin monotherapy

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4

Aspirin use during pregnancy in women with Fontan physiology was not significantly associated with increased bleeding risk compared to no antithrombotic therapy (OR 5.41, 95% CI 0.73-40.4, p=0.067).

Effect: null; OR 5.41; CI: 95% CI 0.73 to 40.4